Absci Corporation Reveals Initial Phase 1 Trial Results for ABS-201

Absci Corporation has announced the interim findings from its Phase 1 HEADLINE™ trial for the drug candidate ABS-201. This information was shared through a press release and a regulatory filing with the SEC. The disclosure provides early insights into the drug's performance during its initial human testing phase.